Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04516161 · ClinicalTrials.gov registry record
EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 1,180
- Enrollment target
NCT04516161 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 1,180 participants.
The verdict
NCT04516161 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 1,180 participants
- Enrollment target
Study Summary
In this observational study researchers want to gather more information about the characteristics of patients treated with Radium-223 (Xofigo) who had survived over a long period of time prostate cancer that had spread to other places in the body and keeps growing even when the amount of testosterone in the body is reduced to very low levels (metastatic castration-resistant prostate cancer, mCRPC). In addition researchers want to identify the factors which may contribute to survival over a long period of time in those patients. Radium-223 (Ra-223) is an alpha particle-emitting radioactive agent approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).
Interventions
- DRUG Radium-223 dichloride (Xofigo, BAY88-8223)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,180 participants |
| Start Date | 2020-08-03 |
| Est. Completion | 2021-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04516161
The ClinicalTrials.gov registry entry for NCT04516161 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Radium-223 dichloride (Xofigo, BAY88-8223) is the first listed.
NCT04516161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04516161 about?
NCT04516161 is a clinical study titled "EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)". In this observational study researchers want to gather more information about the characteristics of patients treated with Radium-223 (Xofigo) who had survived over a long period of time prostate cancer that had spread to other places in the body and keeps growing even when the amount of testosteron...
What is the current status of trial NCT04516161?
This trial is currently completed. The enrollment target is 1,180 participants. The study started on 2020-08-03. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT04516161?
The interventions under investigation include: Radium-223 dichloride (Xofigo, BAY88-8223) (DRUG).
Who is sponsoring clinical trial NCT04516161?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.